CDT Equity Inc. has engaged NJS Foresight Bio-Advisory, LLC to identify and support out-licensing opportunities for selected assets in its solid-form patent portfolio.
The engagement aims to enhance commercial reach and expedite potential licensing and royalty-based transactions, reinforcing CDT's value unlock strategy.
NJS Foresight Bio-Advisory, LLC brings over 20 years of experience in successful out-licensing within biotechnology and pharmaceutical sectors.
Dr. Nick Sarlis, the principal of NJS Foresight, has extensive expertise in clinical and pharmaceutical fields, holding medical and doctoral degrees along with board certifications in Internal Medicine in the U.S.
Enhanced Value through Licensing
The partnership with NJS Foresight aims to leverage CDT's solid-form patent portfolio for value enhancement through out-licensing opportunities.
Experienced Bio-Advisory Engagement
NJS Foresight Bio-Advisory, led by Dr. Nick Sarlis, brings a wealth of experience in successful out-licensing agreements in the biotech and pharmaceutical industries.
Strategic Solid-Form Portfolio
CDT has developed a range of solid-form patents including cocrystals and salts with enhanced properties like improved solubility and up to twenty years of patent protection.
- CDT's focus on solid-form innovation aligns with industry trends responding to patent cliffs and strategic consolidation in the biopharma sector.
- The engagement with NJS Foresight Bio-Advisory reflects CDT's proactive approach to extending product lifecycles and creating value through innovative solid-form assets.
CDT Equity Inc.'s collaboration with NJS Foresight Bio-Advisory signifies a strategic move to unlock value and accelerate opportunities in the solid-form out-licensing space, positioning CDT for continued growth and commercial success.